Key result
Reduced EF is not linked to ischemic or hemorrhagic events in stroke and AF.
Why the study?
Atrial fibrillation and congestive heart failure often coexist and may lead to worse cerebrovascular outcomes, but the risk of ischemic and bleeding events in ischemic stroke patients with AF and reduced ejection fraction was unclear.
Does reduced ejection fraction increase the risk of recurrent ischemic or hemorrhagic events in patients with ischemic stroke and atrial fibrillation?
Cohort (n=3,477)
Does reduced ejection fraction increase the risk of recurrent ischemic or hemorrhagic events in patients with ischemic stroke and atrial fibrillation?
Odds Ratio: 1.25 (95% CI 0.84–1.88)
Absolute Event Rate: 13.4% vs 10.2%
In patients with ischemic stroke and atrial fibrillation, reduced ejection fraction is not associated with short-term recurrent ischemic or hemorrhagic events but is associated with increased mortality or disability.
Reduced ejection fraction does not appear to raise short-term recurrent event risk; leaves open its prognostic value for mortality or disability.
BACKGROUND: Atrial fibrillation (AF) and congestive heart failure often coexist due to their shared risk factors leading to potential worse outcome, particularly cerebrovascular events. The aims of this study were to calculate the rates of ischemic and severe bleeding events in ischemic stroke patients having both AF and reduced ejection fraction (rEF) (⩽40%), compared to ischemic stroke patients with AF but without rEF. METHODS: We performed a retrospective analysis that drew data from prospective studies. The primary outcome was the composite of either ischemic (stroke or systemic embolism), or hemorrhagic events (symptomatic intracranial bleeding and severe extracranial bleeding). RESULTS: The cohort for this analysis comprised 3477 patients with ischemic stroke and AF, of which, 643 (18.3%) had also rEF. After a mean follow-up of 7.5 ± 9.1 months, 375 (10.8%) patients had 382 recorded outcome events, for an annual rate of 18.0%. While the number of primary outcome events in patients with rEF was 86 (13.4%), compared to 289 (10.2%) for the patients without rEF; on multivariable analysis rEF was not associated with the primary outcome (OR 1.25; 95% CI 0.84-1.88). At the end of follow-up, 321 (49.9%) patients with rEF were deceased or disabled (mRS ⩾3), compared with 1145 (40.4%) of those without rEF; on multivariable analysis, rEF was correlated with mortality or disability (OR 1.35; 95% CI 1.03-1.77). CONCLUSIONS: In patients with ischemic stroke and AF, the presence of rEF was not associated with the composite outcome of ischemic or hemorrhagic events over short-term follow-up but was associated with increased mortality or disability.
No takes yet. Share an insight, caveat, or question.
RAF and RENO-EXTEND Investigators (2023) conducted a cohort in Ischemic stroke and atrial fibrillation (n=3,477). Reduced ejection fraction (≤40%) vs. Without reduced ejection fraction was evaluated on Composite of either ischemic (stroke or systemic embolism), or hemorrhagic events (symptomatic intracranial bleeding and severe extracranial bleeding) (OR 1.25, 95% CI 0.84-1.88). In patients with ischemic stroke and atrial fibrillation, reduced ejection fraction was not associated with ischemic or hemorrhagic events (OR 1.25; 95% CI 0.84-1.88).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: